Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Net Cash Flow (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Net Cash Flow for 6 consecutive years, with -$15.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow fell 147.75% to -$15.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.3 million, a 107.54% decrease, with the full-year FY2025 number at -$3.3 million, down 107.54% from a year prior.
  • Net Cash Flow was -$15.3 million for Q4 2025 at Lexicon Pharmaceuticals, down from $28.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $76.3 million in Q2 2023 to a low of -$81.2 million in Q3 2023.
  • A 3-year average of $1.4 million and a median of -$2.4 million in 2024 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: crashed 179.82% in 2024, then surged 2754.03% in 2025.
  • Lexicon Pharmaceuticals' Net Cash Flow stood at $1.3 million in 2023, then skyrocketed by 2279.91% to $32.1 million in 2024, then crashed by 147.75% to -$15.3 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Net Cash Flow are -$15.3 million (Q4 2025), $28.3 million (Q3 2025), and -$12.5 million (Q2 2025).